Fondaparinux: an overview

References

• Petitou M, Duchaussoy P, Driguez PA, Herault JP, Lormeau JC, Herbert JM. New synthetic heparin mimetics able to inhibit thrombin and Factor Xa. Bioorg. Med. Chem. Lett.9(8), 1155–1160 (1999).
   PubMed Web of Science ®Google Scholar
• Petitou M, Hérault JP, Bernat A et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature398(6726), 417–422 (1999).
   PubMed Web of Science ®Google Scholar
• Paolucci F, Clavies MC, Donat F, Necciari J. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin. Pharmacokinet.41(Suppl. 2), 11–18 (2002).
   PubMed Web of Science ®Google Scholar
• Beguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb. Haemost.61(3), 397–401 (1989).
   PubMed Web of Science ®Google Scholar
• Smogorzewska A, Brandt JT, Chandler WL et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch. Pathol. Lab. Med.130(11), 1605–1611 (2006).
   PubMed Web of Science ®Google Scholar
• Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet.41(Suppl. 2), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Lieu C, Shi J, Donat F et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin. Pharmacokinet.41(Suppl. 2), 19–26 (2002).
   PubMedGoogle Scholar
• Mant T, Fournie P, Ollier C, Donat F, Necciari J. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin. Pharmacokinet.41(Suppl. 2), 39–45 (2002).
   PubMed Web of Science ®Google Scholar
• Ollier C, Faaij RA, Santoni A et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin. Pharmacokinet.41(Suppl. 2), 31–37 (2002).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Eriksson BI, Lassen MR, Bauer KA. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J. South Orthop. Assoc.11(4), 182–188 (2002).
   PubMedGoogle Scholar
• Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med.163(11), 1337–1342 (2003).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br. J. Surg.92(10), 1212–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW. Effect of fondaparinux 2.5 mg once daily on mortality: a meta analysis of Phase III randomized trials of venous thromboembolism prevention. Eur. Heart J.10(Suppl. C), C8–C13 (2008).
   Web of Science ®Google Scholar
• The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-Factor Xa activity: a Phase II evaluation. Circulation102(22), 2726–2731 (2000).
   PubMed Web of Science ®Google Scholar
• Büller HR, Davidson BL, Decousus H et al.; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med.140(11), 867–873 (2004).
   PubMed Web of Science ®Google Scholar
• Büller HR, Davidson BL, Decousus H et al.; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med.349(18), 1695–1702 (2003).
   PubMed Web of Science ®Google Scholar
• O‘Donoghue M, Boden WE, Braunwald E et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA300(1), 71–80 (2008).
   PubMed Web of Science ®Google Scholar
• Simoons ML, Bobbink IW, Boland J et al.; PENTUA Investigators. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J. Am. Coll. Cardiol.43(12), 2183–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Granger CB, Eikelboom JW et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol.50(18), 1742–1751 (2007).
   PubMed Web of Science ®Google Scholar
• Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet359(9302), 189–198 (2002).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation114, 774–782 (2006).
   PubMed Web of Science ®Google Scholar
• Coussement PK, Bassand JP, Convens C et al.; PENTALYSE investigators. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur. Heart J.22(18), 1716–1724 (2001).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S et al.; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA295(13), 1519–1530 (2006).
   PubMed Web of Science ®Google Scholar
• Peters RJ, Joyner C, Bassand JP, Afzal R, Cholavicius S, Mehta SR. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur. Heart J.29(3), 324–331 (2008).
   PubMed Web of Science ®Google Scholar
• Oldgren J, Wallentin L, Afzal R et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur. Heart J.29(3), 315–323 (2008).
   PubMedGoogle Scholar
• Bassand JP, Hamm CW, Ardissino D et al. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. The task force for the diagnosis and treatment of Non ST segment elevation acute coronary symdromes of European society of cardiology. Guidelines for the diagnosis and treatment of non ST segment elevation acute coronary syndromes. Eur. Heart J.28, 1598–1660 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction: a report of the Americal College of Cardiology/American heart association task force on practical guidelines. J. Am. Coll. Cardiol.50, e1–e157 (2007).
   Google Scholar
• Schlitt A, Hamilton K, Maegdefessel L et al. Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. J. Heart Valve Dis.15(6), 809–814 (2006).
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood108(5), 1569–1570 (2006).
   PubMed Web of Science ®Google Scholar
• Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin. Thromb. Hemost.32(8), 803–809 (2006).
   PubMed Web of Science ®Google Scholar
• Viles-Gonzalez JF, Gaztanaga J, Zafar UM, Fuster V, Badimon JJ. Clinical and experimental experience with Factor Xa inhibitors. Am. J. Cardiovasc. Drugs4(6), 379–384 (2004).
   PubMedGoogle Scholar